help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schernthaner, G.
Right arrow Articles by Mayr, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schernthaner, G.
Right arrow Articles by Mayr, W. R.

Journal of Clinical Endocrinology & Metabolism, Vol 48, 403-407, Copyright © 1979 by Endocrine Society


ARTICLES

Immunoglobulin G-insulin antibodies and immune region-associated alloantigens in insulin-dependent diabetes mellitus

G Schernthaner, H Ludwig and WR Mayr

The present study was undertaken to determine the importance of immune region-associated alloantigens for susceptibility to insulin-dependent diabetes (IDD), their possible influence on immunoglobulin G-insulin antibody formation, and their clinical significance. Incidence of DRw3 and DRw4 (HLA D-related immune region-associated alloantigens; w, defined by sera dispensed during the Seventh International Histocompatibility Workshop) was found with significantly increased frequency in the IDD patients (n = 50) compared to healthy individuals (n = 107). Subjects positive for DRw3 carry a 4.5-fold increased risk and those positive for DRw4 carry a 2.5-fold increased risk of developing IDD. By analyzing immunoglobulin G-insulin antibody titers in DRw3-positive and DRw3-negative patients (all treated with conventional Lente insulin), a significant tendency for high insulin- binding capacity (IBC) was noted in the latter group, yielding a mean IBC of 2.24 in DRw3-negative and 0.74 in DRw3-positive diabetics (P less than 0.02). A significantly increased insulin dosage was needed for adequate metabolic control in those patients with high IBC (IBC greater than 3.0 U/liter). Patients with high IBC and high insulin requirements were predominantly found to be DRw3 negative. Our data demonstrate that IDD is more closely associated with DRw3 than with all hitherto described HLA A, B, and C locus alloantigens of the major histocompatibility complex. In addition, these immunogenetic factors seem to be of clinical importance by influencing the humoral antiinsulin immune response.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1979 by The Endocrine Society